Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selvigaltin + daratumumab-hyaluronidase + carfilzomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Damora Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
This investigational combination therapy is being evaluated for the treatment of relapsed or refractory multiple myeloma (RRMM). The regimen consists of **selvigaltin** (GB1211), an oral small-molecule inhibitor of Galectin-3 (Gal-3), combined with the standard-of-care triplet therapy known as Dara-Kd. **Daratumumab-hyaluronidase** is a subcutaneous formulation of a CD38-directed monoclonal antibody paired with recombinant human hyaluronidase to facilitate delivery. **Carfilzomib** is a second-generation proteasome inhibitor that induces apoptosis in myeloma cells, and **dexamethasone** is a corticosteroid used to enhance the efficacy of the other agents and manage inflammation. Galectin-3 is often overexpressed in the tumor microenvironment of multiple myeloma and is associated with drug resistance and poor prognosis; by inhibiting Gal-3, selvigaltin is intended to sensitize cancer cells to the cytotoxic effects of the standard-of-care backbone.
- Brand names
- Darzalex Faspro
- Other names
- Selvigaltin + Dara-KdGB1211 + Daratumumab-hyaluronidase + Carfilzomib + Dexamethasone
02
Targets
CD38 (Cluster of Differentiation 38)LGALS3 (Galectin-3)LGALS4GR (Glucocorticoid receptor)26S proteasome
Beyond the preview
Go deeper on selvigaltin + daratumumab-hyaluronidase + carfilzomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selvigaltin + daratumumab-hyaluronidase + carfilzomib + dexamethasone.